Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-3 of 3

Sort by

Sort Order Select

Journal Articles

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Blood (2021) 138 (Supplement 1): 157.

https://doi.org/10.1182/blood-2021-147983

Published: 2021

Journal Articles

Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Adam D. Cohen, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Amrita Krishnan, MD, Rafael Fonseca, MD, Peter A Forsberg, MD, Andrew Spencer, Jesus G. Berdeja, MD, Jacob P. Laubach, MD, Mengsong Li, Voleak Choeurng, Anjali Vaze, Divya Samineni, Teiko Sumiyoshi, James Cooper, Bernard M Fine, Suzanne Trudel

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136985

Published: 2020

Journal Articles

Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Rin Nakamura, Sean Lear, Deanna Wilson, Hartmut Koeppen, Anjali Vaze, Suzanne Trudel, MD MSC, FRCPC, Andrew Spencer, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Adam D. Cohen, MD, Bernard M Fine, Mengsong Li, James Cooper, Teiko Sumiyoshi

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-136980

Published: 2020